Abstract: A pharmaceutical preparation includes a first active component, a second active component and pharmaceutically acceptable excipients. The first active component is at least one selected from the group consisting of a neutral endopeptidase inhibitor and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The second active component is at least one selected from the group consisting of a compound represented by the following formula (I) or a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The pharmaceutically acceptable excipients include one or more disintegrants and/or one or more fillers.
Type:
Grant
Filed:
March 8, 2019
Date of Patent:
May 24, 2022
Assignees:
WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD., WUHAN QR PHARMACEUTICALS CO., LTD., WUHAN ZY PHARMACEUTICALS CO., LTD.
Abstract: A pharmaceutical preparation includes a first active component, a second active component and pharmaceutically acceptable excipients. The first active component is at least one selected from the group consisting of a neutral endopeptidase inhibitor and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The second active component is at least one selected from the group consisting of a compound represented by the following formula (I) or a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The pharmaceutically acceptable excipients include one or more disintegrants and/or one or more fillers.
Type:
Application
Filed:
March 8, 2019
Publication date:
February 25, 2021
Applicants:
Wuhan ll Science and Technology Development Co., Ltd., Wuhan qr Pharmaceuticals Co., Ltd., Wuhan zy Pharmaceuticals Co., Ltd.